May 2, 2024 News by Marisa Wexler, MS Immigrants to Canada see MS risk rising with time in country: Study Among immigrants to Canada, the risk of multiple sclerosis (MS) is higher for those who have spent a greater portion of their life in Canada, a new study reports. The study, “Proportion of Life Spent in Canada and the Incidence of Multiple Sclerosis in Permanent Immigrants,”…
May 1, 2024 News by Mary Chapman MS Canada seeks nationwide participation in awareness month Canada has one of the world’s highest rates of multiple sclerosis (MS) in the world, and this month residents are being urged to come together to raise awareness of and funds for people affected by the neurodegenerative disorder. May is Multiple Sclerosis Awareness Month in Canada, and…
April 30, 2024 News by Andrea Lobo, PhD Committee favors approval of under-the-skin Ocrevus in Europe A committee of the European Medicines Agency (EMA) is recommending the approval of a subcutaneous, or under-the-skin, formulation of Ocrevus (ocrelizumab) for people with multiple sclerosis (MS) in the European Union. The Committee for Medicinal Products for Human Use, known as CHMP, specifically recommended that this new formulation…
April 30, 2024 News by Andrea Lobo, PhD Nektar to develop NKTR-0165 for MS, autoimmune diseases NKTR-0165, an antibody that targets the tumor necrosis factor receptor type 2 (TNFR2), will continue to be developed by Nektar Therapeutics as a candidate for treating multiple sclerosis (MS) and other autoimmune diseases. The experimental therapy was developed under a 2021 collaboration between Nektar and Biolojic…